Eluxadoline

Pediatric
  • TRADE NAME: Viberzi (Forest)
  • INDICATIONS: Irritable bowel syndrome with diarrhea
  • CLASS: Opioid mu receptor agonist
  • HALF-LIFE: 4–6 hours

FDA APPROVAL DATE: 05/27/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Alosetron, Anticholinergics, Atazanavir, Bupropion, Ciprofloxacin, Clarithromycin, Cyclosporine, Dihydroergotamine, Eltrombopag, Ergotamine, Fentanyl, Fluconazole, Gemfibrozil, Lopinavir, Opioids, Paroxetine Hydrochloride, Paroxetine Mesylate, Pimozide, Quinidine, Rifampin, Ritonavir, Rosuvastatin, Saquinavir, Sirolimus, Tacrolimus, Tipranavir

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk

Contra-indicated in patients with known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages/day; a history of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction; severe hepatic impairment (Child-Pugh Class C); severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

Our database has 28 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 09/01/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top